DRUG
linaclotide acetate
oral, once daily.
Status
Completed
Phase
Phase 2
Enrollment
310
Locations
60
Results
Posted
Publications
1
Study summary
The primary purpose of this study is to evaluate the efficacy and safety of administration of linaclotide acetate in patients with chronic constipation.
Interventions
DRUG
oral, once daily.
DRUG
oral, once daily
Timeline
First posted
Nov 22, 2006
Study start
Nov 2006
Primary completion
Dec 2007
Study completion
Feb 2008
Results posted
Mar 5, 2013
Registry updated
Mar 5, 2013
Outcomes
Change From Pretreatment in Weekly Normalized Spontaneous Bowel Movement (SBM) Frequency
Time frame · Change from Baseline to Week 4
Change in SBM frequency during Weeks 1 through 4 of the treatment period from the weekly SBM rate obtained during the pretreatment period.
SBM 75% Responder for the Treatment Period (Based on the Normalized Rate)
Time frame · Change from Baseline to Week 4
A patient was an SBM 75% Responder if the patient was an SBM Responder for ≥3 of the 4 treatment period weeks. For each week of the treatment and postreatment periods, a patient was considered an SBM Responder if for that week the patient 1) completed ≥4 days of IVRS questions,2) had an SBM rate of ≥ 3 for the week, and 3) had an increase in SBM rate of ≥ 1 from their baseline weekly SBM rate.
CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate)
Time frame · Change from Baseline to Week 4
A patient was a complete spontaneous bowel movement (CSBM) 75% Responder if the patient was a CSBM Responder for ≥3 of the 4 treatment period weeks. For each week of the treatment and postreatment periods, a patient was considered a CSBM Responder if for that week the patient 1) completed ≥4 days of IVRS questions,2) had a CSBM rate of ≥ 3 for the week, and 3) had an increase in CSBM rate of ≥ 1 from their baseline weekly CSBM rate.
Change From Baseline in the Weekly Normalized CSBM Rate for the Treatment Period
Time frame · Change from Baseline to Week 4
CSBMs measured daily during the treatment period. During each daily phone call into the IVRS, patients were asked: How many bowel movements did you have today or yesterday after your last call?
Change From Baseline in Stool Consistency (BSFS) Score for the Treatment Period
Time frame · Change from Baseline to Week 4
Stool consistency analyses were performed using the 7-point BSFS, whereby a score of 1 = difficult to pass; 2 = sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges (passed easily); 6 = fluffy pieces with ragged edges, a mushy stool; and 7 = entirely liquid.
Change From Baseline in Straining Score for the Treatment Period
Time frame · Change from Baseline to Week 4
Straining was assessed using a 5-point ordinal scale, whereby a score of 1 = not at all, 2 = a little bit, 3 = a moderate amount, 4 = a great deal, and 5 = an extreme amount.
Eligibility
Inclusion Criteria: * Patient is 18 years of age or older * Patient meets colonoscopy requirements according to the American Gastroenterological Association * Patient meets criteria for chronic constipation including weekly bowel movement frequency requirements and reports one or more symptoms of constipation according to protocol requirements * Patient has successfully completed study requirements with no clinically-significant findings: physical exam, ECG, clinical laboratory tests * Patient is fluent in English Exclusion Criteria: * Patient reports loose or watery stools * Patient meets criteria for IBS including protocol-defined abdominal discomfort or pain * Patient may not take prohibited medications per protocol * Medical diagnoses, medical conditions, or family history that would not make the patient a good candidate for the study or limit the patient's ability to complete the clinical study
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Microbia Investigational Site
Huntsville, Alabama, United States
Microbia Investigational Site
Tucson, Arizona, United States
Microbia Investigational Site
Sherwood, Arkansas, United States
Microbia Investigational Site
Anaheim, California, United States
Microbia Investigational Site
Sacramento, California, United States
Microbia Investigational Site
San Diego, California, United States
Microbia Investigational Site
Boulder, Colorado, United States
Microbia Investigational Site
Bristol, Connecticut, United States
Microbia Investigational Site
Boynton Beach, Florida, United States
Microbia Investigational Site
Port Orange, Florida, United States
Microbia Investigational Site
Tampa, Florida, United States
Microbia Investigational Site
Stockbridge, Georgia, United States
Microbia Investigational Site
Peoria, Illinois, United States
Microbia Investigational Site
Indianapolis, Indiana, United States
Microbia Investigational Site
Clive, Iowa, United States
Microbia Investigational Site
Davenport, Iowa, United States
Microbia Investigational Site
Louisville, Kentucky, United States
Microbia Investigational Site
Monroe, Louisiana, United States
Microbia Investigational Site
Silver Spring, Maryland, United States
Microbia Investigational Site
Boston, Massachusetts, United States
Microbia Investigational Site
Ann Arbor, Michigan, United States
Microbia Investigational Site
Traverse City, Michigan, United States
Microbia Investigational Site
Olive Branch, Mississippi, United States
Microbia Investigational Site
Lincoln, Nebraska, United States
Publications
Related trials
Mayo Clinic · Irritable Bowel Syndrome With Constipation
Not applicable
Recruiting
65
2026-07
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Colorectal Adenoma · Stage 0 Colorectal Cancer AJCC v8
Phase 2
Active, not recruiting
150
2026-07
AbbVie · Functional Constipation (FC) · Chronic Idiopathic Constipation (CIC)
Phase 3
Completed
123
2026-05
University of Nottingham · Cystic Fibrosis (CF)
Early Phase 1
Recruiting
26
2026-05
University of Wisconsin, Madison · Barrett Esophagus · Gastroesophageal Reflux Disease
Phase 1
Completed
43
2026-04
Texas Tech University Health Sciences Center, El Paso · Chronic Constipation · Diabete Mellitus
Phase 4
Active, not recruiting
23
2026-04
Md Mehedi Shahriar · Chronic Idiopathic Constipation · Irritable Bowel Syndrome (IBS-C)
Phase 4
Not yet recruiting
90
2026-02
University of Florida · Patients Scheduled for Colonoscopy
Phase 1 / Phase 2
Recruiting
10
2026-01
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.